Mitsubishi Tanabe Pharma America, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2015-01-01
- Employees
- 101
- Market Cap
- -
Clinical Trials
28
Trial Phases
3 Phases
Drug Approvals
2
Clinical Trials
Distribution across different clinical trial phases (27 trials with phase data)• Click on a phase to view related trials
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Esophageal CancerGastric CancerBiliary Tract CancerPancreatic Ductal Adenocarcinoma (PDAC)Breast CancerOvarian CancerCervical CancerEndometrial Cancer
- Interventions
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-07-20
- Lead Sponsor
- Mitsubishi Tanabe Pharma America Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT06943521
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP
- Conditions
- Erythropoietic Protoporphyria (EPP)X-Linked Protoporphyria (XLP)
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Mitsubishi Tanabe Pharma America Inc.
- Target Recruit Count
- 165
- Registration Number
- NCT06144840
- Locations
- 🇺🇸
Marvel Clinical Research, LLC, Huntington Beach, California, United States
🇺🇸University of California at San Francisco, San Francisco, California, United States
🇺🇸University Of Miami School Of Medicine, Center For Liver Diseases, Miami, Florida, United States
Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy Subjects
- First Posted Date
- 2022-02-15
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- Mitsubishi Tanabe Pharma America Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT05241535
- Locations
- 🇺🇸
Daytona Beach Clinical Research Unit, Daytona Beach, Florida, United States
🇺🇸Dallas Clinical Research Unit, Dallas, Texas, United States
Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Mitsubishi Tanabe Pharma America Inc.
- Target Recruit Count
- 202
- Registration Number
- NCT05151471
- Locations
- 🇺🇸
Woodland Research Northwest, LLC, Rogers, Arkansas, United States
🇺🇸UF Health Cancer Center/Clinical Trials Office, Gainesville, Florida, United States
🇺🇸Emory University - School of Medicine, Atlanta, Georgia, United States
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
- First Posted Date
- 2021-08-16
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Mitsubishi Tanabe Pharma America Inc.
- Target Recruit Count
- 301
- Registration Number
- NCT05005975
- Locations
- 🇺🇸
University of California at San Francisco - CSF Porphyria Center, San Francisco, California, United States
🇺🇸University Of Miami School Of Medicine, Center For Liver Diseases, Miami, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- Next